Discuss nivo1 + ipi3 or nivo + rela; anti-PD1 monotherapy only if not suitable for combination
All three approaches are evidence-based first-line options for unresectable or metastatic melanoma. The combination options may improve disease control but have different toxicity profiles; anti-PD-1 monotherapy remains guideline-supported based on disease tempo, comorbidities, toxicity tolerance, and patient preference rather than only combination ineligibility.